Disc Medicine, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Disc Medicine, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($62.32M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($55.25M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($55.25M) | Nov 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($34.09M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($34.09M) | May 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($34.09M) | Aug 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($26.60M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($26.35M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($26.35M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($26.95M) | May 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($26.95M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($26.95M) | Aug 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($14.12M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.95M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($15.95M) | Nov 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($22.78M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($22.78M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($22.78M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.15M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.58M) | Aug 11, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($67.70M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($61.41M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($39.95M) | May 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($32.86M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.85M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($31.46M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($18.96M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($17.33M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($25.13M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.48M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($12.02M) | Aug 11, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.96M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($18.45M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($16.32M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($16.49M) | May 6, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($7.95M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($6.67M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($9.63M) | May 13, 2021 |